3
Announcements
Trials
Browse
Landscape
Status
Unknown
1
Sponsor Class
OTHER
7
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Neoplasms
9
Carcinoma, Non-Small-Cell Lung
7
Colorectal Neoplasms
6
Breast Neoplasms
6
Prostatic Neoplasms
5
Papillomavirus Infections
5
Ovarian Neoplasms
4
Neoplastic Cells, Circulating
4
Uterine Cervical Neoplasms
3
Uterine Cervical Dysplasia
3
Lung Neoplasms
3
Melanoma
2
Lymphoma, Follicular
2
Leukemia, Myeloid, Acute
2
Hematologic Neoplasms
2
Carcinoma, Hepatocellular
2
Thymic aplasia
1
Stomach Neoplasms
1
Solid Tumor, Adult
1
Small Cell Lung Carcinoma
1
Respiratory Distress Syndrome
1
Recurrence
1
Rectal Neoplasms
1
Radiation Injuries
1
Pulmonary Disease, Chronic Obstructive
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Opioid-Related Disorders
1
Interventions
Brentuximab Vedotin
27
pembrolizumab
13
Nivolumab
11
Dacarbazine
8
Vinblastine
7
Doxorubicin
7
Gemcitabine
6
Bendamustine Hydrochloride
6
plerixafor
5
fludarabine
4
Rituximab
4
Granulocyte Colony-Stimulating Factor
4
Cyclophosphamide
4
Azacitidine
4
abexinostat
3
Melphalan
3
Filgrastim
3
Etoposide
3
Busulfan
3
Bleomycin
3
umbralisib
2
relatlimab
2
pegfilgrastim
2
mocetinostat
2
itacitinib
2
givinostat hydrochloride
2
givinostat
2
fludarabine phosphate
2
durvalumab
2
cc-486
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Hodgkin Disease
×
Blood Specimen Collection
×
Clear all
NCT05735704
2025-03-26
SANGUINE
JaxBio Ltd
Unknown
3,000 enrolled